| HOME >> MEDICINE >> TECHNOLOGY |
(55,892)
(b)(c) Cost of services--Cost of alliances(50,958)
(e)
(18,835)
(e) Selling, general and administrative ("SG&A")(28,558)
(c)(f)(g)
(50,323)
(c)(f) Research and development--Contingent consideration fair value adjustments(23,198)
(h)
(9,042)
(h) Acquired in-process research and development(149,868)
(i)
(4,000)
(i) Legal settlements(56,779)
(j)
(2,400)Restructuring, acquisition-related and other costs(161,190)
(k)
(73,913)
(l) Amortization of intangible assets(629,400)(365,016)(1,170,386)(579,421)Operating income1,170,386580,225Interest expense, net14,214
(m)
19,034
(m) (Gain) loss on extinguishment of debt2,45533,325Gain (loss) on investments, net-(1,769)Other income (expense), net including translation and exchange --Income before (recovery of) provision for income taxes1,187,055630,815Provision for income taxes127,802
(n)
77,098
(n) Total Adjustments to Net income $ 1,059,253$
553,717Earnings per share:Diluted:Total Adjustments to Net income$
3.38$
.68Shares used in per share computation313,584329,010(a) See footnote (a) to Table 2a.(b) ASC 805, accounting for business combinations requires an i
'/>"/>
| SOURCE Valeant Pharmaceuticals International, Inc. Copyright©2012 PR Newswire. All rights reserved |